Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
ArriVent BioPharma logo in transparent PNG and vectorized SVG formats
Logo de ArriVent BioPharma aux formats PNG transparent et SVG vectorisé
VIDEO. Les premiers produits affichant un nouveau logo arrivent dans ...
ArriVent Receives FDA Breakthrough Therapy Designation for
ArriVent Biopharma Launches with Up To $150M in Series A
ArriVent BioPharma, Inc. - AnnualReports.com
Biopharmaceutical Therapeutics Company ArriVent Biopharma Raises $155 ...
ArriVent BioPharma Reports Second Quarter 2024 Financial Results
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for ...
ArriVent BioPharma (AVBP) IPO deck
ArriVent Biopharma Closes $155M in Series B Financing | citybiz
Our Investment in ArriVent
Newtown Square Pennsylvania based ArriVent Biopharma is raising ...
ArriVent BioPharma's (AVBP) Outperform Rating Reaffirmed at Oppenheimer
Arrivent Biopharma | LinkedIn
ArriVent Biopharma Collaborates with Lepu BioPharma to Develop and ...
Citi boosts share target for ArriVent BioPharma by US$4 on positive ...
About - ArriVent BioPharma
ArriVent BioPharma enters exclusive license with Lepu Biopharma for ...
ArriVent BioPharma, Inc. (AVBP) Stock Price, News, Quote & History ...
Arrivent BioPharma, Inc. (Arrivent BioPharma, Inc.) - 药物管线_专利_临床试验_投融营收 ...
Series A - ArriVent Biopharma
AVBP - ArriVent BioPharma Inc - Cotação, história, resultados e ...
ArriVent BioPharma (AVBP) Stock Price, News & Analysis
ArriVent BioPharma (AVBP) - BPA (bénéfice par action)
ArriVent Biopharma - BioSpace
ArriVent BioPharma Secures Global Rights to Promising Cancer Drug ...
ArriVent Biopharma Launches with Up To $150M in Series ...
ArriVent BioPharma (AVBP) Stock Price & Overview
Programs - ArriVent BioPharma
ArriVent Launches in Newtown Square With Plans for New Cancer Drug
ArriVent Announces a Multi-Target ADC Collaboration with Alphamab
AVBP: ArriVent BioPharma Inc. Latest Stock Price, Analysis, News and ...
ArriVent licenses ADC from $100M biobuck deal with Aarvik – Optimal Dose
ArriVent BioPharma Reveals Promising Data on Firmonertinib - Investors ...
ArriVent Biopharma Seeks $100 Million IPO For Lung Cancer Drug (Pending ...
ArriVent Biopharma IPO investment analysis
ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A ...
Clear Street Initiates Coverage of ArriVent BioPharma (AVBP) with Buy ...
AVBP - ArriVent BioPharma | Fundamentei
ArriVent Biopharma | LinkedIn
ArriVent goes Further into PACC mutations | ApexOnco - Clinical Trials ...
ArriVent BioPharma's $75M Public Offering: A Necessary Dilution for ...
Arrivent Launching Phase III Trial of Firmonertinib for EGFR PACC ...
Home - ArriVent BioPharma
Arrivent Biopharma Locks in $155M to Support Drug Candidate Pipeline ...
ArriVent takes in $175M from second biotech IPO of the year - Biotech Today
ArriVent BioPharma: ArriVent inks $47 Mn cancer drug deal with Lepu ...
ArriVent BioPharma, Inc. Reports Earnings Results for the First Quarter ...
ArriVent BioPharma aims to raise $75M in public stock offering ...
ArriVent BioPharma, Inc. - AnnualReports.co.uk
ArriVent Biopharma issues upsized $175M IPO, becomes region's first ...
ArriVent wows investors with promising China-developed lung cancer ...
ArriVent BioPharma, Inc. - AVBP - Stock Price Today - Zacks
Mintz Advises ArriVent Biopharma in $155M Series B Financing | Mintz
ArriVent Biopharma Files for $100M IPO to Develop Potential Lung Cancer ...
Week In Review: Arrivent BioPharma Raises $175M In IPO For In ...
intelligence360.io on LinkedIn: ArriVent Biopharma has filed a notice ...
Les nouveaux gTLDs arrivent : pourquoi et comment posséder votre dot ...
ArriVent BioPharma, Inc. (AVBP) 2023年年度报告「NASDAQ」.pdf_三个皮匠报告
ArriVent BioPharma will apply the IPO cash toward furmonertinib, which ...
Les SFM Intro arrivent
Pharma365 - Lévothyrox® : deux nouveaux dosages arrivent
Mintz Advises on ArriVent BioPharma’s Upsized IPO on the Nasdaq Global ...
Arrivent Consulting — Kommo
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ ...
In this photo illustration the Emergent BioSolutions logo of an US ...
Les logos éclairés arrivent
高瓴为第一大股东：艾力斯合作伙伴，ArriVentBiopharma,Inc.要美股IPO了！_财富号_东方财富网
ArriVent登陆纳斯达克
Portfolio – OrbiMed
Graphic
连续2家biotech成功IPO！2024年产业已见曙光 继 CG Oncology 公司成功完成3.8亿美元IPO之后，临床期生物技术公司 ...
バイオ医薬品治療薬のグローバルな開発を行う"ArriVent Biopharma"がSeries Bで$155Mを調達
艾力斯祝贺其合作伙伴ArriVent Biopharma成功在美国纳斯达克挂牌上市医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
制药企业ArriVent举办敲钟仪式：公司市值7亿美元 高瓴是股东 - 知乎
Covetrus Connected Partners| Covetrus UK
高瓴投的制药企业ArriVent纳斯达克上市：市值6亿美元 华裔创办_腾讯新闻
高瓴投的制药企业ArriVent纳斯达克上市：市值6亿美元 华裔创办 - 知乎
Working at Arrivant | Glassdoor
BioTechのArriVent、EGFR PACC変異NSCLCを対象とする第3相ALPACCA試験で初回患者投与を開始
Client Success - LifeSci Search
再获顶级投资机构青睐，明星初创新融资将高达1.45亿美元，主打国产创新药出海_财富号_东方财富网
12亿美元：乐普生物临床前ADC新药授权给ArriVent Armstrong 2025年1月22日， 乐普生物 宣布将创新ADC新药 ...
Sirona Capital - 2026 Investor Profile, Portfolio, Team & Investment ...
